Close Menu

coronary artery disease

A spontaneous coronary condition that is overrepresented in young women had a polygenic risk score linked to lower-than-usual atherosclerosis-related heart disease risk.

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

In PLOS this week: method to detect SARS-CoV-2 directly from swabs, gene expression patterns in Kaposi's sarcoma, and more.

The GWAS of more than 200,000 Japanese individuals across 42 diseases identified 25 novel loci shared between Japanese and European populations.

Trialing It Out

The New York Times reports Pfizer and BioNTech have also started a trial of their mRNA-based vaccine for SARS-CoV-2 in the US.

Although polygenic risk scores for coronary artery disease can slightly improve standard risk assessment tools, the predicted clinical impact remains small.

Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.

The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.

Yale School of Medicine researchers analyzed patients and families affected by early-onset coronary artery disease to uncover mutations in CELA2A.

Reuters reports that on the launch of Verve Therapeutics, a biotech focused on using gene editing to treat cardiovascular disease.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.